Centre de Référence Maladies Rares DEVGEN Constitutif Sud, CHU de Montpellier, France; Laboratoire de Génétique de Maladies Rares, EA7402, Université de Montpellier, Montpellier, France; Laboratoire de Génétique Moléculaire, IURC, CHU de Montpellier, Montpellier, France.
Centre de Référence Maladies Rares DEVGEN Constitutif Sud, CHU de Montpellier, France.
Eur Urol. 2021 Apr;79(4):507-515. doi: 10.1016/j.eururo.2020.12.036. Epub 2021 Jan 16.
Next-generation sequencing (NGS) is generally used for patients with severe disorders of sex development (DSD). However, NGS has not been applied extensively for patients with hypospadias only, and most affected children do not benefit from an etiological diagnosis.
To evaluate the clinical usefulness of NGS for patients with hypospadias, regardless of severity.
DESIGN, SETTING, AND PARTICIPANTS: Prospective multicenter research included 293 children with glandular to penoscrotal hypospadias (no undescended testis and no micropenis). After excluding likely pathogenic androgen receptor (AR) variants by Sanger sequencing, an NGS panel tested 336 genes including unexplored candidates in 284 patients.
The rate of pathogenic and likely pathogenic variants was assessed using REVEL, ClinVar, and in-house tools (Captain-ACHAB, MobiCNV, and MobiDetails).
Likely pathogenic variants were identified in 16 (5.5%) patients with both Sanger sequencing and NGS taken into account. Some genes were related to DSD (AR, NR5A1, HSD17B3, and MAMLD1), but reverse phenotyping revealed two syndromic disorders with midline defects (MID1) and alteration in the retinoic acid signaling pathway (RARA). Coverage analysis revealed an 18q deletion. Identification of likely pathogenic variants increased with hypospadias severity. Other variants of unknown significance (VUSs) in genes implicated in hypogonadotropic hypogonadism, Noonan syndrome, and genital tubercle development were also identified. Genetic study mainly focused on exonic variants, and most cases remain unexplained.
NGS reveals minor forms of DSD, undiagnosed syndromes, or candidate rare variants in new genes, indicating that even patients with mild hypospadias benefit from advanced sequencing techniques. Early molecular diagnosis would help improve follow-up at puberty and medical counseling for initially undiagnosed syndromes. Future studies will improve the diagnosis by investigating the contribution of VUSs.
Next-generation sequencing enables simultaneous testing of numerous genes and should not be limited to disorders of sex development cases. Even patients with mild hypospadias would benefit from early diagnosis of a genetic defect implicated in sex development or other syndromes.
下一代测序(NGS)通常用于严重性别发育障碍(DSD)患者。然而,NGS 尚未广泛应用于单纯性尿道下裂患者,大多数受影响的儿童无法获得病因诊断。
评估 NGS 对各种严重程度的尿道下裂患者的临床应用价值。
设计、地点和参与者:前瞻性多中心研究纳入了 293 例具有性腺-阴茎阴囊型尿道下裂(无未降睾丸和无小阴茎)的儿童。在排除可能的致病性雄激素受体(AR)变异后,284 例患者通过 Sanger 测序排除了可能的致病性 AR 变异,然后进行了包含 284 个未探索候选基因的 NGS 面板检测。
使用 REVEL、ClinVar 和内部工具(Captain-ACHAB、MobiCNV 和 MobiDetails)评估致病性和可能致病性变异的发生率。
考虑到 Sanger 测序和 NGS 的结果,16 例(5.5%)患者检测到可能的致病性变异。一些基因与 DSD 相关(AR、NR5A1、HSD17B3 和 MAMLD1),但反向表型分析揭示了两种伴有中线缺陷的综合征(MID1)和视黄酸信号通路改变(RARA)。覆盖分析显示 18q 缺失。尿道下裂严重程度越高,可能的致病性变异的检出率越高。还在与促性腺激素低下性性腺功能减退症、诺南综合征和生殖结节发育相关的基因中发现了其他意义不明的变异(VUSs)。遗传研究主要集中在外显子变异,大多数病例仍无法解释。
NGS 揭示了轻微形式的 DSD、未确诊的综合征或新基因中的候选罕见变异,表明即使是轻度尿道下裂患者也受益于先进的测序技术。早期分子诊断有助于改善青春期的随访和对最初未确诊综合征的医学咨询。未来的研究将通过研究 VUSs 的贡献来提高诊断水平。
下一代测序可以同时检测多个基因,不应仅限于 DSD 病例。即使是轻度尿道下裂患者,也将受益于性发育或其他综合征相关遗传缺陷的早期诊断。